Index

Abbott, F.M. 295
Abbott Laboratories 89, 124, 162, 226–7, 266, 336
Able Laboratories 85–6
Aboriginal Australians 326, 328
ABPI Code of Practice 107, 187
Abshear, Dan 188–9
Accelerating Access Initiative 159
Access to Medicine Foundation 377–8
accidents 23, 94–6, 153, 279
accountability 76–7, 276, 286, 300, 310, 339, 358, 376
ACS (New York) 44
Actiq 136
active substances, quality of 77–80
Adams, Stanley 233–4, 272, 320, 371
addiction 40, 50, 172, 173
ADHD 124–9, 182, 337
administrative liability 254–65
administrative penalties 316, 325
adverse events 87, 146, 280
advertising 104, 305–9
in developing countries 147–8
direct-to-consumer 27, 141–3, 149–50, 164, 181, 307
Internet 144–7, 149–50
media role 150, 174, 179–80
misleading 106–51, 299–300, 316
regulation 148–51
stealth 131–2, 150
targeting health professionals 115–37
advocacy groups 343, 348, 349, 361
Africa 260–61, 277, 377
South 166–7, 257, 262, 380, 381, 387
Sub-Saharan 101, 168, 257
AGA Medical Corporation 199
Agent Orange 48
Ahnigook Pharm 188
AIDS Healthcare Foundation 218
air pollution 99–100
air transport/safety 322–3
Albania 74, 260
albendazole 261
Alexion Pharmaceuticals 88
allergic reactions 44, 78, 92
allergies 71, 140–41, 236
Alpha Therapeutic Corporation 79
Alpharma Generics UK 250
Alzheimer’s disease 41, 107, 282
Ambien 146
American Enterprise Institute 211
American Journal of Cardiology 113
American Medical Association 123–4,
130
American Psychiatric Association 120,
125–7, 174–5, 178
American Psychological Association 51
Americans with Disabilities Act 332
Amgen 164, 335–6
amphetamines 126, 127, 172
Amylin Pharmaceuticals 42
analgesics 18, 53, 84–6, 135, 138
AndroGel 251
Angell, Dr Marcia 164, 171, 176, 219,
283
animal studies 4, 5, 18–19, 22, 54, 60,
62, 139, 274
ethics 42, 43, 47, 50–52, 65–6
pre-marketing studies 27, 33–4
Annals of Internal Medicine 283
anti-depressants 35, 114, 135, 179, 238
anti-inflammatories 32, 119, 135, 138,
169, 180
antibiotics 45, 58–9, 81, 94, 97, 141,
249, 259
antihistamines 236–7
antipsychotics 62, 116, 135, 146–7,
164–5, 190, 197–8, 282, 336
antitrust laws 104, 232–3, 250, 298, 316, 342
antiviral agents 157
Apotex 238–9, 252
Apothecon Inc. 190
appetite stimulants 5, 136, 260
appetite suppressants 3, 14, 36, 139, 172
Aranesp 335
Argentina 40, 46, 54, 63
Armour Pharmaceutical Company 78–9
Armstrong, Lance 336
arsenicals 19–20
arthritis 117–18
Arthur Andersen 373
artemisinin 13
artusenate 206–7
ASEAN 383, 387
Aspirin 18–19, 35–6, 106
AstraZeneca 336, 337
patents 232–3, 237–8
promotion 113–14, 116, 135, 150
atenolol 85–6
Ativan 146
atorvastin 238
audit reports 299, 300, 350
Australia 81, 168, 257, 281, 301, 353
Competition Commission 297, 319
Institute of Health and Welfare 280
promotion 117, 131–2
regulation 296–7, 301
responsive law 319, 321–2
Australian Journal of Bone and Joint Medicine 131–2
authoritarian capitalism 365, 368, 371
autism 184
Avandamet 88
Avandia 34, 114
Aventis SA 234
avermectin 261
Avocats sans Frontières 353
Avon, J. 232
Ayerst 122, 174, 248–9
azithromycin 261
AZKO Nobel NV 200
AZT 218, 221
banking sector 368–9, 371–3, 374–6
Barr 249–50
BASF 234
Bate, Roger 211
‘bathtub’ manufacturers 313
Baxter Healthcare 78, 79, 97
Baycol 39–40
Bayer 18–19, 78–9, 192, 249, 266, 336
BCCI 360, 373
Becker, G.S. 317, 318
Beecham’s Pills/Powders 140
behavioural economics 317–19
Bennett, B. 96
benoxaprofen 119, 169, 180
benzodiazepines 41, 55, 111, 121
‘Best Price’ statute 190, 222
Bextra 135, 337–8
Bhopal disaster 355
BHP-Billiton 355
biologicals, patents on 241–3
BioMarin Pharmaceutical 98
Biopharm (India) 74
biosimilars, patents on 241–3
biotechnology 71, 136, 181, 291, 383
open-source 267, 285, 294–5, 364, 370, 380–81
Black, Conrad 360
blacklisting system 187
Blasetto, James 113
blood products 47, 48, 78–9
Bodnar, Andrew 252
Boehringer–Ingelheim 61–2, 257
Boesky, Ivan 372
Boldrin, M. 294
Borger, Julian 152
bounty hunters 334, 354–5
Bradford Hill, A. 22
Braithwaite, J. 33, 82, 87, 94–5, 194, 213, 272–3, 275–6, 297, 303, 310, 331, 373
Breggini, Peter R. 126, 178
bribery 169, 198, 213–14, 314, 373, 388
abroad 199–201
considerations 187–9
enforcement 342, 355
of health professionals 189–91
payments to desist 249–53
regulation 191–6, 277, 285, 303, 364
BRIC countries 364, 380–81, 382–3
Index 393

Briggs, G.G. 31
Bristol Myers Squibb 97, 190, 210, 336
generic competition 250, 251–3
pricing 221, 226
regulation 293, 295
Britain 8, 20, 112, 177
HSE 90–91, 92
Medical Research Council 41
NHS 111, 240
OFT 250
Proprietary Association of GB 138
British Generic Manufacturers Association 165–6
British Medical Journal 63–4, 157–8, 180, 182–3, 206, 265, 283
British Petroleum 389
Brodie, Lord 352
Brönnimann, Dr Roland 234
Bu-Spar 250
Bucy, P. 332, 345–6, 347, 348
Budkie, Michael 51–2
Buffet, Warren 278
burden sharing 287–8
Burke, Matthew 337
Byetta 42

Cambodia survey 203
Canada 165–6, 219–20, 254, 263, 383
cancer 92–3, 107, 136, 220–22, 253, 264
breast 61, 94, 123, 150
oral 32
prostate 256, 337
capacity-building 353, 354, 357
capital punishment, corporate 303–4, 312, 313, 353
capitalism 67, 312, 362, 374
authoritarian 365–6, 369–9, 371
BRIC 380–81
ethical 283, 377–80
new 271, 272, 283, 363–90
old 363–6
regulatory 364–70, 382
car industry 312, 321, 374–5
Caraco Pharmaceuticals 71, 81, 84–5
cartels 232, 233–5, 267, 272, 315
Catalent Pharma Solutions 92
caveat emptor 17
Ceclor CD 259
Cefazolin for Injection 78
Celebrex 338
censorship 116, 138, 149, 273
Center for Drug Evaluation/Research 170
Center for Media and Democracy 182
Centers for Disease Control 89, 112
Centre for Addiction and Mental Health (University of Toronto) 172, 173
Centre for Public Integrity 171
Centre for the Study of Ethics and Rights (India) 60–61
Cephalon 136
cephalosporin 94, 259
Chan, Dr Margaret 156, 157
Chandler, Dr Janet 339
Chandrasekaran, S. 235–6
‘channel stuffing’ 210–11
charity see philanthropy
‘Cheaper Medicines Law’ 197
children 106, 140–41, 190
ADHD 124–9, 182, 337
drug trials 43–4, 46, 58–9
China 99–100, 371
corruption and 187, 191, 193–4, 196, 199–200
Chiron 71–2
cholesterol–reducing drugs 4, 33, 39–40, 111, 113, 238
chromatography data system 85–6
chronic disorders 40–42, 224
Cialis-One-a-Day 143
Ciba 53, 126
Ciba–Geigy 54–5, 64–5
Cibuco River 97–8
Cipla 226
ciprofloxacin 249, 250
Citizens Commission on Human Rights 178
civil liability/law 20–26, 254–65
Civil Rights Act 332
Clarinex 237
Clarinex 71, 195, 236–7
Clinard, M.B. 255
clinical studies 309
developing countries 57–63, 298
clioquinol 37, 53–5, 64, 67
co-regulation 271
Cochrane Collaboration 157, 282–3
corruption 49
Coffee, J.C. 351, 352, 371
Cole, G. 96
Combivir 226
Committee for Proprietary Medicinal Products (of EC) 191, 213
Common Rule 48–9, 50
compensation 209–10, 310
developing countries 58, 59
victims 7, 31, 32, 257, 303, 311, 325–7, 332, 348, 357, 371, 376
competition 215, 228, 233, 248–53, 257
compliance 386
audit reports 299, 300, 350
internal reports 343, 348–50
positive regulation 286, 298–300, 303
responsive justice 310, 314, 318–21
compounding centres 74–5
compulsory licensing 230, 257, 263, 285
drug diplomacy 364, 367, 380
manipulation and 162, 179–80
Concord Laboratories 76
consumer(s) 329, 332, 353
direct-to (advertising) 27, 140–3, 149–150, 164, 181, 307
protection 332, 342
safety see safety (of drugs)
contamination 88–9, 93, 96, 100, 103
cross- 80–85
Contergan 23
contraception 79
oral 28–9, 31, 34, 91–2, 98, 111, 116
contraindications 15–16
continuous improvement 292, 298, 306, 329, 350, 380
controlled studies 22, 27
Convention on Human Rights and Biomedicine 45
conversational regulation 319–20, 323
Cook County Hospital 339
Cooter, R. 354
Copley Pharmaceutical 72
copyright 294, 383
corporate capital punishment 303–4, 312, 313, 353
corporate crime 255, 310
corporate culture 154, 185, 302, 387
Corporate Europe Observatory 160–61
Corporate Integrity Agreement 66, 136, 185, 195, 330, 336, 339, 347, 358–9, 379, 387–8
Corporate Manslaughter and Corporate Homicide Act (UK) 8, 207
corporate social responsibility 379
corruption 186–201, 213–14, 366
enforcement 354–5, 357
manipulation 168, 169, 171, 277
positive regulation 298, 302–3
see also counterfeiting; fraud
corticosteroid injections 75
costs
of compensation 209–10
of innovation 215–18, 278
profits and 148, 216, 218, 253, 291
Council of Europe 157–8
Council for International Organizations of Medical Sciences 43
counterfeiting 101, 186, 197, 227, 281
detection of 205–6, 342
enforcement 313, 342, 364, 366
essence of 201–2
extent 203–5, 213–14, 273–4, 277
policy/law (principles) 206–9
see also corruption; fraud
cover-up 322–3, 359, 384
creative destruction 363
Crichton, A. 125
crime
  economic theory 317–19
  normative theory 314–16
  in the suites 278–82
Crime Victims Fund (USA) 257
criminal law 7–8, 184–5, 376
  just vulnerability 310–12
  privatizing enforcement 272, 286,
  331–62, 387
  responsive 310–30
  strengths/weaknesses 282–4
  symbolic power 313–14
criminal liability 20–25, 26, 254–65
  criminological perspective 271–84
Critical Path Initiative 288
  cross-contamination 80–85
Crucell 160
Cui, C.W. 98–9
culpability 376
Curtin University 117
Cytodone Technologies 139–40
Cytosol Laboratories 83
DART method 205
data exclusivity 243–6
data mining 117
deaths (causes) see homicide;
manslaughter; murder
DeFelice, Dr Stephen 111
dementia 41, 107, 135, 282, 336
Depakote 336
DepoCyte 73
depression 23, 35, 52, 125, 135, 282
DES (diethylstilbestrol) 55
Descoursaux, Eric 234
design of studies (faults) 29–33
detector/detoxing 115–18
detection 283, 318–19, 320–21, 324
deterrence 301, 317–24
  trap 312, 352–3, 371
developing countries 112, 230, 265, 266
corruption 203–6, 214, 364, 366
dumping 102, 259–60, 328, 353
enforcement 334, 353–7, 387
industrial charity 259–62, 267, 279
manipulation and 161–2, 167–8, 277
pricing in 219, 223–7, 256, 279
production in 101, 277
  promotion in 147–8
research and 56–65, 298, 369–70
diabetes 34, 60, 114, 172, 182
Brown Medical 117
Diagnostic and Statistical Manual
  125–7
diarrhoea 37, 44, 53, 55
dietary supplements 139, 140
diethylene glycol 20–21, 64, 67, 193
Diflucan 82, 258–9
Dilantin 86–7
direct-to-consumer advertising 27,
  141–3, 149–50, 164, 181, 307
direct interference 166–7
discrediting 63–5, 178–9, 248–53
disease mongering 112, 120–29, 150,
  181
distributive justice 326
DNA technology 242, 243
Doctors without Borders 56, 58, 144,
  160, 167, 225, 329, 382
Dod–Frank reforms 334, 355
Doha Declaration 162, 179, 230, 264,
  266
Dolan, Peter 2553
Donovan, Professor Rob 117
double-blind studies 22, 28
  ‘double-dipping’ billing 222
Dow Chemical 48
Draho, P. 291–2, 295–6, 356, 367–8,
  382, 386
driver behaviour 320–22
  ‘drug compendia’ 176
drug diplomacy 214, 271, 283, 363–90
Drug Information Association 171
  ‘drug lag’ 287
Drug Price Competition and Patent
  Term Restoration Act 246, 251
Drugdex Information Service 176
drugs
  competition see competition
  disasters (three classic cases) 20–25
discredited 63–5
dumping 102, 259–60, 328, 353
esential 158, 180, 223, 227, 259,
  364, 385
evergreening 236–41, 277, 293
  long-term use 40–42
me-too 108, 219
older (neglect of) 53–5
orphan 245–6, 288, 351
over-the-counter 137, 138–43, 154
registration 194–6, 287
research see research
safety see safety (of drugs)
‘Drugs for Neglected Diseases Initiative’ 288
Drugs and Therapeutic Bulletin 144
‘dual-plaintiff design’ 345
Dukes, G. 8, 275, 295, 331
Durand, Douglas 337

Eastern Caribbean Drug Service 367
Eckard, Cheryl 103
Economist, The 248, 342
Edict of Salerno 19
education 57, 58, 172–3
see also learning; universities
efavirenz 225
efficacy 315
drugs 13–14, 16, 18, 22–8, 42, 53–5
research 26, 27–8, 65–8, 351
$800 Million Pill, The (Goozner) 216
elderly people 112, 219–20
Electronic Communications Privacy Act 332
elimination approaches 208–9
‘Elixir of Sulfanilamide’ 20–21
Elsevier 131
employees 76–7, 326–7
protection 90–96
enforcement 329, 330, 363
corporate crime 353–7, 390
entrepreneurs 348–51
False Claims Act 286, 320, 333–9, 340–47, 355, 387
innovation and 384, 386–7, 390
integrated approach 285–309
positive regulation 271, 285–309
privatization 272, 286, 331–62, 387
regulatory pyramid 185, 288–92, 299, 311–12, 328, 353, 356
scapegoating 276, 300, 302, 323, 358
Enron 361, 372
Entero-Vioform 53–4
environmental protection 96–100, 332
equity fines 286, 330, 371, 388
privatizing enforcement 333, 343, 351–3, 355, 359–60
erectile dysfunction 143
Viagra 109–10, 123, 140, 141
esomeprazole 237
essential drugs 158, 180, 223, 227, 259, 364, 385
efficiency 343, 361
animal studies 42–3, 47, 50–52, 65–6
ethical capitalism 283, 377–80
ethical dissenters 275, 384–6
human studies 42–50, 57–8, 65–6
leadership 329–30
regulatory theory and 272, 311, 330
European Commission 70, 232, 234, 240, 272, 281, 371
European Court of Justice 232
European Medicines Agency 35, 38, 73
European Parliament 167
European Union 160, 166, 232, 242, 245
Evans Medical 82, 88
‘evergreening’ 236–41, 277, 293
Excerpta Medica 131–2
execution (of offenders) 193
expenses 74, 164, 216, 218, 255–6, 258
explosions 94–5, 273
Facebook/Facebook Share 145
‘failure to warn’ cases 143–4
False Claims Act 135–6, 151, 188, 190, 195, 214, 222, 273, 385
enforcement 286, 320, 333–47, 355
FBI 252, 275, 282
FDA (USA) 4, 260
on corruption 195–6, 198, 204, 213
Critical Path Initiative 288
enforcement 287, 338, 342, 355, 384
generic competition 249, 251
manipulation 155, 157, 169–72, 176
manufacturing practices and 67–8, 70–74, 76–9, 81–3, 85–9

Graham Dukes, John Braithwaite and J. P. Moloney - 9781783471102
Downloaded from Elgar Online at 03/15/2019 09:42:41AM
via free access
misleading promotion 116, 124, 132, 134–6, 139–40, 143–7, 149–50
Modernization Act 170–71, 172
patents 238, 240–41, 246
Federal Food, Drug and Cosmetic Act 21
Federal Food and Drugs Act 19, 21
federal pre-emption 143–4
Femara 61
Feuillet, Georges 21–2
Fiddes, Dr Robert 31
fiduciary duty 198
finance capitalism 368–9, 374
financial sector 181, 279, 312–13, 339, 365, 384
see also banking sector
Financial Times 189
Finegold, D. 329
fines 190–91, 200, 232, 234, 255
equity see equity fines
per diem 300
qui tam see qui tam
Fluvirin 71–2
FOMS 187–8, 198
Food and Drugs Act (USA) 19, 21
Forcades i Vila, Teresa 123, 163–4
foreign aid 291, 366
Foreign Corrupt Practices Act (US) 194, 199–201, 334, 355, 357, 366
forgery 191
France 19, 21–2, 172
fraud 31, 42, 114, 169, 315–16, 340
‘channel stuffing’ 210–11
developments 186–7, 209–14
malpractice and injury 212–13, 282
manufacturing practices 72, 85–6
on payment schemes 210
substandard medicines 211–12
see also corruption; counterfeiting
Fraud Enforcement and Recovery Act 340
freedom of information 41, 168
Friedrichs, D.O. 255, 279
FTC 250–52, 342
funding agencies 197–8
fungal infections 75, 143, 258
Gable 239, 239
Gates, Bill/Gates Foundation 278–9, 288, 378, 383–4, 386
GA VI 159–60, 279
gene technology 296
Genentech 38
General Accounting Office, US 221
General Motors 375
generic competition 248–53
Genotropin 136
Geodon 175
Gerahty, Thomas 337
ghostwriting 108, 130–31, 132, 150, 338
gifts 174–5, 187, 190, 199, 348
Giuliani, Rudolf 372, 374, 387–90
Glaxo 79, 192, 297–8, 337
GlaxoSmithKline 250, 257, 266, 378
corruption and 189–90, 193–4, 198
enforcement and 335, 337, 361
manipulation and 160, 169–70
manufacturing practices 83, 88–9, 103
patents 238, 247
pre-marketing evidence 33–5
pricing 218, 219, 222, 226
promotion 107, 114, 135, 140–41
trials 46, 61
Gleevec 146, 239
Glenmullen, Joseph 179
Glivec 239, 264
Global AIDS Alliance 225–6
Global Corporate Integrity Investigation 390
Global Fund to fight HIV/AIDS, Tuberculosis and Malaria 279
GM rice proteins 44
Goldacre, B. 237–8, 283
Good Laboratory Practice (GLP) 276, 290, 292, 298–300, 315, 348, 350
Good Manufacturing Practice (GMP) 69, 70–71, 77, 81, 89, 276, 290, 292, 298, 300, 315, 322, 325, 348, 350
Google 147
Goozner, M. 216, 219
Gotzsche, P. 273, 282, 283
government(s) industry and 163, 263–5, 266 manipulation and 163–8
Government Accountability Office 149, 151
Grassley, Charles 334, 385
Greenspan, Alan 369
Index

industrial charity 258–63, 277–8
industry, government and 163, 263–6
influenza vaccine 71–2, 157
information technology 294–5
informed consent 44, 46, 48–9, 58, 62–3
Infuse 32, 36–7
injury, fraud and 212–13, 282
innovation 277
costs 215–18, 278
enforcement and 384, 386–7, 390
ethics and 272, 283
investment in 285, 351, 370
open-source 267, 285, 294–5, 364, 370, 380–85
patents see patents
regulation and 285, 286, 290–92
rewards/prizes 290–92
inside information 105, 275–6, 337, 348, 349
insider trading 316
insomnia 3, 7, 18, 34, 41
inspection 191–7, 318, 348, 350
Institute of Medicine 49, 142, 280
insulin 67–8, 94, 115
intellectual property 180, 199
drug diplomacy 364–5, 367, 369–70, 381, 383–5
TRIPS see TRIPS agreement
WIPO 384
interferon 182
Internal Revenue Service 334
International Association of Whistleblowers 339–40
International Conference of Drug Regulatory Authorities 208
International Conference on Harmonization 43, 287
International Covenant on Civil and Political Rights 45
International Criminal Court 387
International Federation of Pharmaceutical Manufacturers’ Association 156, 385–6
international organizations, manipulation and 155–62
International Scientific Committee of US Pharmacopoeia 208
Internet 144–7, 149–50, 181, 204, 209, 286, 307, 348–51
Intervet International BV 200
investment 285, 351, 370
Iraq 200–201, 377
Italy 191–2, 293–4, 371
ivermectin 261–2
Jackall, R. 154
Janssen-Cilag 197–8
Japan 54–5, 95, 383
Johns Hopkins University 44
Johnson and Johnson 62, 155, 160, 164, 197, 378
Jones, Peter 113
Jorge, M.F. 232
Joshi, Shashank 60
Journal of the American Medical Association 123–4, 130, 283
Jureidini, J. 177
justice
responsive 310–30
restorative see restorative justice
Kassirer, J. 283
Kennedy Hearings 48
Kenya 148, 262
Kesselheim, A.S. 232
Kessler, Dr David 132
key opinion leaders 177
Khan, A. 23
kickbacks 189, 190, 198, 335, 336
Kligman, Albert 48
knowledge, new (management) 35–42
Korea Pharmaceutical Manufacturers 188
Krimsky, Sheldon 131–2
Kytril 222–3
Lacey, Federal Judge 252–3
Laing, R.D. 216
Laos 205–6
large firms 337–40
see also multinational companies
Lasagna, Lou 217
Lasix 87
Lauridsen, Ernst 385
law
  administrative liability 254–65
civil 20–25, 26, 254–65
criminal see criminal law
  reform (failures) 331–4
learning 322–3, 324, 379
Leisinger, Klaus 64–5
Lenz, Widekund 24
leukaemia 93, 145, 146, 239, 264
Levine, D.K. 294
Lexapro 146
Librium 106, 121
licensing system 42, 51, 70
  see also compulsory licensing
Light, D.W. 217–18
Lilly, Eli 194, 217, 259–60, 282
  enforcement and 336, 339
  manipulation and 169, 173, 179, 183
  promotion by 119, 135, 142–3
limit-setting (in promotion) 110–14
Lipitor 238
litigation 167
lobbying 230, 231, 263
  manipulation 152–3, 158, 161,
    163–6, 172
  regulation and 285, 293
Long Island 94–5
looting/looters 359–62
lopinavir/ritonavir 226–7
Los Angeles Times, The 170
Losec 107, 232, 237
Lotronex 169–70
Love, J. 267, 290
Lupron 256
Lyrica 338
McCloy, J.J. 303, 373, 387–90
  ‘madness’ 125
Mahler, Halfdau 385
malaria 13, 56, 101, 203, 206–7, 212,
  223, 279, 281
malpractice 66, 114, 212–13, 273
manipulation 277
  court proceedings 183
  educational institutions 172–3
  essence of 152–5, 184–5
governments 163–8
  health professions 173–9
  international organizations 155–62
  legislative subterfuge 184
  media 179–80
  public opinion 181–3
  regulatory agencies 168–72
  stock market 181
manslaughter 206, 207, 280–81
manufacturing practices
  absolute standard 69–75
  accommodation and equipment 75
  active substances 77–80
  developing countries 101
  employee protection 90–96
  nanotechnology 102–3
  offshore abuses 101–2
  packaging 82–4
  protocols and routines 80–82
  quality assurance/control 84–9
  record keeping 89–90
  staff accountability 76–7
  standards 103–5
marketing
  aggressive/misleading 106–51
  guiding and regulating 148–51
  see also advertising; promotion
Martini, Nello 192
Maryland State Commission 178–9
Massengill Company 20–21
Maxamamine 62
Maxim Pharmaceuticals 62
Maxwell, Robert 359–61
Mayo Clinic 126
me–again patents 236–41, 277, 293
me–too patents 108, 219
MedWatch Program (FDA) 87
Médécins sans Frontières (MSF) 56, 58,
  144, 160, 167, 225, 329, 382
media, manipulation and 179–80
Mediator 172
Medicaid 135, 176, 338–9
  corruption and 190, 195, 198, 210
  pricing and 218, 222, 223, 256
Medical Council of India 168
Medicare 135, 164, 238, 338–9
  corruption and 190, 210
  pricing and 222, 223, 256
Index

Index

medicine development 13–15 standards see standards
substandard 211–12
Pharmaceuticals, corporate crime and public health

Nuremberg trials 47
Nurofen 84
nursing homes 304, 374, 379–80

Obama administration 335, 339–40, 374–5
obesity 14, 52
oestrogen 55, 91–2, 94, 98–9, 111, 122–3, 136, 174, 182
off-label promotion see promotion
offshore manufacturing 101–2
Oil-for-Food Programme 200, 201
oil industry 303, 373, 377, 388–90
omeprazole 107, 232, 237
onchocerciasis 260–61, 262
‘One World Health’ 288
Onondaga Treatment Plant 97
open-source
biotechnology 267, 285, 294–5, 364, 370, 380–81
start-ups 380–81, 384
opiates 297–8
‘opinion leaders’ 174, 177
Opren 119
Oraflex 119
oral contraception see contraception
oral rehydration fluids 44
‘Orange Book’ 251
Organization Man, The (Whyte) 154
Organon 34, 115, 200–201
orphan drugs 245–6, 288, 351
Ortho Pharmaceutical Company 155, 181
over-enforcement 345–6
over-the-counter drugs 137, 138–43, 154
overpricing see pricing
Ovral 91
Oxfam 307, 329, 382, 385, 386

Pacira Pharmaceuticals 73
packaging 82–4
paclitaxel 218, 220–22, 250, 253
Palmlund, I. 174
Palombi, L. 296
Pan Pharmaceuticals 81
Pandya, Anand 178

‘panic attacks’ 121
Paonta Sahib facility (Ranbaxy) 85
Papua New Guinea 355
Par Pharmaceutical Companies Inc. 176
paracetamol 207
parallel imports 167, 232, 253–4
parasitaemia 206
parenteral fluids 82, 88, 89
Paris Convention 229
paroxetine 250

patents
on biologicals/biosimilars 241–3
broadening of 235–6
data exclusivity 243–6
evergreening 236–41, 277, 293
health innovator 265–7
history/development 228–31
monopolies see monopolies/
monopoly

Offices 291, 293, 366–8, 378, 385
pricing policies 233
prizes/rewards 290–91
reform 292–8
suppression of discoveries 241
transfer pricing 246–8
virtues/vices 231–3
walls of 292–3, 295
Patient Protection and Affordable Care
Act 340
Paxil 35, 114, 238
Paxil CR 88
payment schemes, fraud on 210
payments to desist 249–53
payouts 63, 334, 342, 344–5, 359, 373
penalties
administrative 316, 325
liability and 254–5
qui tam cases see qui tam
value of 202, 209–10, 211, 282, 335–7
whistleblower share 276, 330, 339–46, 359–61, 384
see also fines; prison sentences;
sanctions
penicillin 20, 28, 94
Pepcid 190, 336
perindopril 240
Petit, P. 357
## Index

<table>
<thead>
<tr>
<th>Page</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pfizer 30, 58–9, 164, 174, 199, 266</td>
<td>in Developing world 219, 223–7, 256</td>
</tr>
<tr>
<td>Central Stability Laboratory 71, 73–4</td>
<td>freedom and 215–28</td>
</tr>
<tr>
<td>charity by 258–9, 261–2</td>
<td>monopolies and 233, 281</td>
</tr>
<tr>
<td>enforcement 336, 337–9, 352</td>
<td>overpricing 104, 219, 232, 247, 255–8, 262</td>
</tr>
<tr>
<td>manufacturing practices 82, 84, 99, 104</td>
<td>transfer 246–8, 315</td>
</tr>
<tr>
<td>pricing 219, 238</td>
<td>in the West 219–23</td>
</tr>
<tr>
<td>pharmaceutical industry</td>
<td>prisoners 46–50, 277</td>
</tr>
<tr>
<td>criminological perspective 271–84</td>
<td>prizes/rewards 290–92, 296</td>
</tr>
<tr>
<td>invincibility belief 263–5</td>
<td>problem–solving pyramid 311–12, 328</td>
</tr>
<tr>
<td>responsive criminal law 310–30</td>
<td>Procrit 203–4</td>
</tr>
<tr>
<td>Pharmaceutical Inspection Convention 104</td>
<td>Proctor and Gamble 124</td>
</tr>
<tr>
<td>Pharmaceutical Laboratories 76–7</td>
<td>production see manufacturing practices</td>
</tr>
<tr>
<td>Pharmaceutical Research and Manufacturers' Association 166</td>
<td>professional bodies 178</td>
</tr>
<tr>
<td>Pharmacia 74, 136, 337–8</td>
<td>professionals see health professionals</td>
</tr>
<tr>
<td>Pharmacopoeia 77, 208</td>
<td>profits 8, 29, 258, 278, 313, 320</td>
</tr>
<tr>
<td>pharmacovigilance 27, 40, 87</td>
<td>costs and 148, 216, 218–19, 253, 291</td>
</tr>
<tr>
<td>philanthropy 267, 274, 279, 288</td>
<td>monopoly 250, 369</td>
</tr>
<tr>
<td>drug diplomacy 377–8, 383–4, 386</td>
<td>profitable fields 52–3, 67</td>
</tr>
<tr>
<td>industrial charity 258–63, 277–8</td>
<td>regulation 167, 176, 287, 293, 301</td>
</tr>
<tr>
<td>Philippines 196–7</td>
<td>Prometa 50</td>
</tr>
<tr>
<td>phocomelia 24, 37</td>
<td>promotion 306–9</td>
</tr>
<tr>
<td>PhRMA 164, 165</td>
<td>advertising and marketing 109–10</td>
</tr>
<tr>
<td>Pickering, F.C. 91</td>
<td>aggressive/misleading 106–51, 299–300</td>
</tr>
<tr>
<td>Piriteze 141</td>
<td>costs 108, 109, 150–51</td>
</tr>
<tr>
<td>Piriton 141</td>
<td>in developing world 147–8</td>
</tr>
<tr>
<td>placebos 22–3, 28, 44–5, 49, 59, 62</td>
<td>federal pre–emption 143–4</td>
</tr>
<tr>
<td>Plavix 252–3</td>
<td>guiding/regulating marketing 148–51</td>
</tr>
<tr>
<td>Pogge, T. 267, 291</td>
<td>Internet 144–7</td>
</tr>
<tr>
<td>Poggiolini, Duilio 191–2</td>
<td>misrepresentation 315–16</td>
</tr>
<tr>
<td>pollution 97–100, 355</td>
<td>off-label 114, 116, 134–7, 175–6, 188, 190, 282, 336</td>
</tr>
<tr>
<td>positive regulation 271</td>
<td>over-the-counter drugs 138–43</td>
</tr>
<tr>
<td>patent reform 292–8</td>
<td>targeting health professionals 115–37</td>
</tr>
<tr>
<td>responsive regulation 298–301</td>
<td>Proprietary Association of GB 138</td>
</tr>
<tr>
<td>restorative justice 302–5</td>
<td>Protek 187–8, 198</td>
</tr>
<tr>
<td>strategies 285, 286–8, 302–9</td>
<td>protocols, manufacturing 80–82</td>
</tr>
<tr>
<td>supports and sanctions 288–92</td>
<td>Provigil 136</td>
</tr>
<tr>
<td>poverty 52, 112, 378</td>
<td>Prozac 173, 179</td>
</tr>
<tr>
<td>pre-marketing evidence 27, 33–5</td>
<td>psychotic state 183</td>
</tr>
<tr>
<td>precipitant promotion 113–14</td>
<td>see also antipsychotics</td>
</tr>
<tr>
<td>pregnancy 23–5, 37, 55, 94, 175</td>
<td>Public Citizen 70, 209, 307, 329, 383</td>
</tr>
<tr>
<td>Premarin 174</td>
<td>public health 329, 343, 351</td>
</tr>
<tr>
<td>prescription drugs 107, 141–3, 170, 172</td>
<td>pricing</td>
</tr>
</tbody>
</table>
regulation 298, 304, 308–9, 320, 323, 359, 370, 374
public interest 296, 297–8
public opinion 181–3
Puerto Rico 97–8, 99, 103
Punch, M. 359, 360, 361
punishment 271, 283, 327
corporate capital 303–4, 312–13, 353
responsive law 310–14, 317–19, 323–4
see also deterrence; fines; penalties; prison sentences; sanctions
pyramid strategy
positive regulation 288–92, 298–309
regulatory 168–9, 171, 283, 311, 324, 329, 356, 367, 370–77
restorative justice 185, 302–5, 324, 326–8
QAMSA 101
quality
active substances 77–80
assurance 70, 84–9, 104
control 70–71, 73, 76, 79–80, 84–9, 101, 102, 104
qui tam 324, 330, 366
whistleblowers 276, 339–46, 359–61, 384
quinine hydrochloride 87
Quinney, R. 255
Radium Hospital (Norway) 32
Ranbaxy 85
randomized double–blind controlled clinical trial 22
Reagan administration 287
Rebetron 182
record keeping 89–90
Red Cross 79
regulation 66–7, 324–5, 361
conversational 319–20, 323
corruption and 191–7, 277
ethical theory and 272, 311, 330
gaming of 16–17, 185, 274, 277, 282
manipulation and 168–72
manufacturing practices 69–105
marketing 148–51
networked 57, 272, 276, 286, 296, 355–7, 363, 382, 386
positive 271, 285–309
pyramid see pyramid strategy
responsive 298–301, 304, 320, 356–7, 359, 382
see also self-regulation; standards
Regulatory Affairs Professionals Society 185, 386
regulatory capitalism 364–70, 382
Reiter, K. 49
release test methods 85
Relenza 156
Rennie, D. 283
republican political theory 357
research 76–7, 224, 263
costs/funding 215–18, 253, 273–4, 278, 290, 370
design (execution/faults) 29–33
developing countries 56–65, 370
drug safety 26–8, 65–8, 351
investment 285, 351, 370
misdirection 52–5
regulation 66–7, 285, 290, 304, 306–8
suppression of discoveries 241–3
in universities 172–3, 369–70, 381–3
Resource Conservation/Recovery Act 99
‘responsive fault’ 376
responsive justice 310–30
responsive regulation see regulation
restorative justice 271, 310, 319, 373
enforcement and 271, 330, 343, 358–9
pyramid strategy 185, 302–5, 324, 326–8
Retin-A 48, 155, 181
Reuben, S.S. 338
Revue Prescrire 144
Reye’s syndrome 35–6, 106
rhBMB–2 236–7
Rhône-Poulenc 234
ribavirin 182
Richter, Judith 158–9
RICO 332
Index

Ringrose, Peter 293
risk 14–16, 28, 34, 36, 38, 43–6, 368–9
Risperdal 62, 197–8
Ritalin 126, 127
ritonavir 226–7
river blindness 260–61, 262
robber barons 359–62
Robinson, J. 154
Roche 38, 157, 371
‘rogue executive’ 302, 375
Rosenbaum, Jerrold 179
Rossi, Pasqualino 192
Rost, Peter 337
rosuvastatin 113–14
Rotapharm 101–2
routines, manufacturing 80–82
Royal College of Physicians 112, 177
‘Royal Ordonnance’ (France) 19
rules, liability and 254–5
Russia 62, 187–8, 198
Rwanda 259–60
Saddam Hussein regime 200
SAEN 51–2
safety (of drugs) 315, 315, 350–51, 379
efficacy and 13–14, 16, 18–19, 22–8, 42, 53–5
employee protection 90–96
manufacturing practices 69–105
regulation 15, 16, 18–19, 57, 286, 288, 305
research 26–8, 65–8, 351
study (faults) 29–33
St Elizabeth’s Hospital 341
sale of goods law 17–18
Salvarsan 19–20
samples (free) 133, 190
sampling (quality control) 88
sanctions 191–2, 376, 379
liability and 254–5
positive regulation 271, 285–309
pyramid 288–92, 298–9, 301, 304–5, 308, 311–12, 363
see also deterrence; fines; penalties;
prison sentences; punishment
Sandoz 74
Sanofi 194
Sanofi-Aventis 63
scapegoats/scapegoating 276, 300, 302, 322, 332, 326, 358–9
scaremongering 129–30
Scarff, R.W. 91
Schering 31
Schering-Plough 70, 99, 182, 194–5, 200, 236–7
schizophrenia 125, 135, 175, 197, 336–7
Schumpeter, J. 363
Schwarz Pharma 99
Scientific Protein Laboratories 78
Scott, T. 237
Scully, Thomas 238
SEC 108, 199–200, 210, 216, 334
sedatives 4, 23–5, 121, 361, 365, 390
seeding trials 108
seizure (of drugs) 88–9, 209
self-medication 141
self-regulation 271, 274, 276, 298–9, 321, 325, 356, 370
Selim, Jim 81
Sero 134
Seroque/Seroque XL 116
Serostim 134
Seroxat 250
Servier 172, 238–9, 240
settlements, liability and 254–5
sexual dysfunction 123–4
Shamy, M.Y. 92
shareholders 66, 312, 351–2
Sheen, Mr Justice 4–5
‘Shirley System’ 129
Shover, N. 359
side-effects 7, 14, 22, 33–4, 60
knowledge management 35–40, 41
unethical practices 44–5, 48
Silverman, Ed 180
Silverman, Morton 65
Sino Biopharmaceutical 191
Sjöström, J. 25, 175
Skapinker, M. 186
Slaughter, A-M. 355
Smith, C.P. 91
Smith, R. 283
Smith, Tony 180
Smith Kline and French 245
SmithKlineBeecham 79, 132, 261, 336, 344
SMON 54–5
smuggling 224
social anxiety disorder 121, 181
social justice 329
socialism 312, 362, 370–77, 384–5
Society of Cardiac Patients 182
Soeken, Donald 341
Softenon 23
Soliris API 88
Solvay 251
Soma 110–11
SOMO 60–61, 62, 63
South Africa 166–7, 257, 262, 380, 387
spinal bone product 32, 36–7
stability tests/studies 85
Stalinon 21–2, 26
Standard Operating Procedures 70, 81–2
standards 276
absolute 69–75
current (basis) 25–9
defining (in promotion) 110–14
emergence/creation of 15–20
manufacturing practices 69–105
safety see safety (of drugs)
technical (of studies) 13–68
start-ups 382, 383–4, 385
open–source 380–81, 384
starting materials, quality of 77–80
State FDA (China) 193
State IPO(China) 199
Statute of Monopolies 229
stealth advertising 131–2, 150
Stellar 113
‘Stiff Nights’ 140
Still, G.F. 125
stock market 181, 219, 384
Stough, Dr Austin 48
strengths-based pyramid 56–7, 171, 288–92, 299, 305, 311, 363, 379
substandard medicines 211–12
Sudbø, Dr Jon 32
suicide 173
sulphonamide/sulphanilamide 20–21, 64
Sun Pharmaceuticals of India 61
Sunday Times, The 361
‘sunshine laws’ 189, 348
supports
positive regulation 271, 285–309
pyramid 56–7, 171, 288–92, 298–9, 304, 305, 308, 311, 363
Sutherland, E. 278
swine fever 130, 158, 161, 387
vaccine 146, 155, 156–7, 265
symposia 119–20
Syrup of Ipecac 87
Tagamet 245
Takeda-Abbott (TAP) 190, 256–7, 336–7
Tamiflu 146, 155, 156–7, 265
Tasigna 145
Tasmanian Poppy Growers Association 298
taxation 306–8, 333–4, 370, 373
avoidance 247, 274, 316
evasion 101, 315, 316, 348
havens 301, 315, 348, 360–61
Taxol 218, 220–22, 253
Taxpayers Against Fraud 339, 343, 382
technology transfer 291
Test Aankoop (in Belgium) 143
testimonials 109–10
testosterone 92, 124, 136
Thailand 162, 179–80, 191, 227, 262
Thalidomide 4, 37, 67, 275, 326, 350, 361, 365, 390
Grüenthal case 23–5, 175
Thatcher government 287
Therapeutic Goods Administration 81
thiomerosal 184
Three Mile Island 388–9, 390
Times, The 361
Timor Sea 373, 389–90
Titanic, The 279
Tokyo District Court 54
tort law/reform 331, 332, 345, 346–7
Toxic Anterior Segment Syndrome 83
toxic waste 96–100
toxicity tests 27, 50, 54
trade 197, 364
agreements 162, 231, 293, 384
Index 407

secrets 242, 350–51
trademark law 201
transfer pricing 246–8, 315
tranquilizers 41, 55, 106, 110–11, 121
Treaty on the Functioning of the EU 240
triazolam 331
Trileptal 188
TRIPS agreement 227, 230, 246, 264, 384
manipulation 161, 162, 167
positive regulation 290–91, 293–4
tropical diseases 13, 56–7, 261, 383
Trovan 45
trust 31, 65, 248, 254, 329, 354, 390
truth (in promotion) 106–9
tuberculosis 56, 159, 279, 281, 295, 364
Tufts University 216–17, 218
Tylenol 84

Uganda 61–2
UK see Britain
ulcers 107, 232, 237, 241
UNESCO 292
unethical practices 42–52, 65–6
UNICEF 160, 259, 260
United Nations 155, 159, 200
Millennium Project 223
universities 117, 172–3, 217, 369–70, 381, 382–3
University of Rochester 217
University of Toronto 172–3
Upjohn 34, 338
USA
Department of Health and Human Services 49, 188
Department of Justice 188, 199, 210, 257, 341–2, 344–5
False Claims Act see False Claims Act
FDA see FDA (USA)
Fund for UNICEF 259, 260
Minerals Management Service 389–90

regulatory statutes, dual–track 324–5
SEC 108, 199–200, 210, 216, 334
‘vaccine court’ 184
vaccines 32, 46, 71–3, 82, 86, 157, 259
GAVI 159–60, 279
Vagelos, P.R. 225, 261–2
Van der Linde, Hans 182–3
Vega Baja wastewater treatment plant 97–8
Venice 228–9
Ventria Bioscience 44
Viagra 109–10, 123, 140, 141
Vicks Vaporub 139
victims 95, 320, 346–7
compensation for see compensation
justice for 325–8, 331, 332
Vioxx 34, 37–8, 52, 64, 109, 117–18, 130, 190, 336, 338, 390
Viramune 61–2
vitamins 111, 233–4, 272
von Liebig, Justus 18
vulnerability/vulnerable 57–63, 310–12

Wakefield, A.J. 32
Wall, M. 220–21
Wall Street 180, 372–3, 374, 376
Wani, M. 220–21
Warburton, R. 217–18
Warner–Lambert 86–7, 94–5, 97–8, 134
warranties 17–18
Washington Post, The 182
water pollution 97–9
Watrous, R.M. 91
Webecker, Joseph 183
Wellbutrin 114, 135
Welch 115
Wellquest Company 60
Werlen, Thomas 188
whistleblowers 75, 85, 188–90
qui tam 276, 330, 339–46, 359–61, 384
responsive law 320, 330, 357, 359
scapegoating 276, 358–9
Stanley Adams 233–4, 272, 320, 371
Pharmaceuticals, corporate crime and public health

Whitaker, R. 174–5, 179, 284
white-collar crime 278, 335
Whyte, W.H. 154
wilful blindness 314–15
Willman, David 170–71
Wilson Foundation 122
WIPO 384
Withering, William 18
Women’s Health Initiative 123
Woodcock, Janet 170
Woods, Sir Kent 38
World Bank 162, 353, 386
World Customs Organization 203
World Health Assembly 156, 162, 202, 385–6
World Health Organization 6, 25–6, 44, 54, 226, 259, 261
drug diplomacy 384, 385–6
IMPACT 202, 208
on manufacturing practices 70, 75, 81
on manipulation 155–62, 167–8
on promotion 126, 148
regulation 70, 75, 81, 148, 168, 191, 288, 297, 386
World Medical Association 43
World Trade Organization 161, 231, 384
Doha Round see Doha Declaration
TRIPS see TRIPS agreement
Worldcom 372
Wrage, A.A. 197, 205
Wyeth Pharmaceuticals 91
Xanax 146
Xenadrine 139–40
Xolair 45
Zerit 226
Zheng Xiaoyu 193
Zhong–Yuan Yang, Dr 208
Zithromax 141
Zocor 190, 336
Zoladex 337
Zyprexa 135, 282, 336